Herpes Simplex Keratitis Treatment Market Snapshot (2023 to 2033)

The anticipated size of the herpes simplex keratitis treatment market in 2022 was US$ 4,237.2 million and is estimated to be US$ 4,442.2 million in 2023. There are a few key factors that are anticipated to expand the herpes simplex virus treatment market such as:

  • Rise in the prevalence of herpes simplex virus infection.
  • Increase in the rate of new infections.
  • The advancement in the treatment and diagnostic methods.
  • Growing government funding.
  • Upsurge in the mode of transmission of the infectious disease.

According to the Future Market Insights analysis report, herpes simplex keratitis treatment market is projected to expand at a CAGR of 6.1% between 2023 and 2033, totaling around US$ 8,022.9 million by 2033.

The ongoing development of advanced healthcare infrastructures worldwide is likely to augment the demand for herpes simplex keratitis treatment in the assessment period. Herpes simplex virus keratitis is an infection of epithelial cells that are present on the surface of the eye. It also causes retrograde infection of nerves that serve the cornea.

Primary infection usually leads to the swelling of eyelids and the conjunctiva, as well as itchy, white lesions on the corneal surface. Some of the additional symptoms include sinusitis, mild to acute dryness, and dull pain in the eye.

Recurrent infection is often caused by the reactivation of the virus and transportation of the same from the nerve axon to sensory nerve endings. Antiviral treatment either in the form of topical medications or oral administration of famciclovir or valacyclovir for 10 to 14 days is required when keratitis occurs. The condition is diagnosed by a slit-lamp examination. The rising adoption of topical therapy owing to its high efficacy is anticipated to propel the market in the future years.

Attributes Details
Projected Forecast Value (2022) US$ 4,237.2 million
Projected Forecast Value (2023) US$ 4,442.2 million
Projected Forecast Value (2033) US$ 8,022.9 million
Growth rate 6.1% CAGR
Forecast period 2023 to 2033

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Herpes Simplex Keratitis Treatment Market Historical Analysis (2018 to 2022) Vs. Forecast Outlook (2023 to 2033)

Global herpes simplex keratitis treatment market expanded at a CAGR of 3.9% between 2018 and 2022. Growth forecasts remain optimistic, with the market predicted to exhibit a CAGR of 6.1% between 2023 and 2033.

Therapeutics segment includes valacyclovir drug considerably dominates the market as it is cost-effective, easily available, and effective in blocking the virus from reproducing in the body, thereby having advantages to controlling the symptoms of an outbreak.

Valacyclovir is most widely used for cold sores determinable to its high absorption rate. Efforts and investments are done for providing vaccination for the disease condition which is anticipated to boost the growth of the vaccine segment.

Prominent Drivers Spearheading Herpes Simplex Keratitis Treatment Market Growth

Increasing Research and Development Activities

Increasing research and development activities conducted by numerous key players to launch new drugs are set to propel the market in the near future. The rising cases of herpes simplex virus type 2 and herpes simplex virus type 1 across the globe is another key factor that is estimated to bode well for the herpes simplex keratitis treatment market growth.

According to the World Health Organization (WHO), nearly 3.7 billion people under the age of 50 years have herpes simplex virus type 1 infection across the globe, whereas around 491 million people aged 15 to 49 years have herpes simplex virus type 2 infection. These numbers are set to surge in the upcoming years, thereby propelling the growth in this market.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Challenges Faced by the Herpes Simplex Keratitis Treatment Industry

Cost of Herpes Simplex Keratitis Treatment is High

The cost of herpes simplex keratitis treatment is high. As per a study conducted by a team of researchers at Saint Louis University, Missouri, people in the United States spend tens of millions for the treatment of this condition. Moreover, people, especially in emerging economies may not be able to spend a huge amount and this may hamper the herpes simplex keratitis treatment market growth in the future.

Region-wise Analysis

North America is Emerging as an Opportunistic Herpes Simplex Keratitis Treatment Market

North America is projected to remain at the forefront by procuring the notable herpes simplex keratitis treatment market share of 34.7% in the near future. Further, the increasing prevalence of infections associated with the herpes simplex virus in the United States is a leading factor that is likely to propel the market with a value share of 32%.

Sexually active individuals or those who have had 3 or more sex partners in their lifetime are at a high risk of developing type 1 keratitis.

According to the Centers for Disease Control and Prevention (CDC), 1 in 5 individuals have a Sexually Transmitted Infection (STI), such as genital herpes in the United States, totaling around 68 million infections. In addition to that, new STIs total around US$ 16 billion in direct medical costs. This trend is projected to continue throughout the evaluation period, thereby boosting North America’s market.

Asia Pacific is Contributing to the Growth of the Herpes Simplex Keratitis Treatment Market

The growing number of new product launches by reputed companies is expected to fuel the sales of herpes simplex keratitis treatment options in Asia Pacific. The surging number of clinical trials in China, India, and Australia is another significant factor that is estimated to augur well for the market. China is forecasted to expand at a CAGR of 7.8%, whereas India is forecasted to expand at 7.1% CAGR. Australia is forecasted to capture 8.4% CAGR. For example,

  • A hospital in Ghaziabad, India, reported the first-ever case of herpes simplex virus infection that was termed as ‘very dangerous.’ Doctors discovered that COVID-19-recovered patients who have weak immune systems are most likely to develop this condition. Thus, the rising incidence of life-threatening disorders across Asia Pacific is projected to accelerate the market.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-wise Analysis

Acyclovir has a Dominant Share in the Market

Acyclovir has a significant position in the market with a value share of 29.8%. Acyclovir and its analogs, are considered to be the inhibitors of viral DNA replication and are the only approved medicines for HSV that are used for infection therapies.

Topical Route of Distribution Holds a Leading Position in the Market

Topical route of distribution holds a leading position in the market with a value share of 43.8%. Host tissue (cornea) may become effective for HSV infection and repetition with topical, intravitreal, or systemic medications. In humans, recurrent ocular HSV-1 disease has mainly contributed to the usage of prostaglandin agonists, corticosteroids, and inhibitors of angiogenesis.

Market Competition

The global herpes simplex keratitis treatment market contains a large number of big and small players. Some of them include Aurobindo Pharma, GlaxoSmithKline, Cipla, Blistex, Mylan, Vectans Pharma, Dr. Reddy's Laboratories, Bausch Health, Novartis International AG, and Jubilant Cadista among others.

The majority of the leading companies are increasingly focusing on mergers and acquisitions, as well as geographical expansions to gain a competitive edge in the market. Meanwhile, a few other key players are striving to come up with innovative products to fulfill the high unmet needs of patients across the globe.

  • In December 2022, Global private equity fund Blackstone’s planned to submit a non-binding bid to acquire the entire 33.47% promoter stake in Cipla, India’s third-largest generics company by revenues, which had sparked a debate over the company’s future.
  • In February 2023, Novartis, had mentioned that it is on track to become a pure-play innovative medicines company, uniquely positioned to leverage its global scale and R&D platforms. Its six multi-billion brands5 now represent 32% of our Innovative Medicines sales and are growing 26%.
  • Pluvicto and Scemblix had very strong launch performances, and the Leqvio launch continues to progress. Pivotal Ph3 readouts for two iptacopan studies and Pluvicto in earlier lines of therapy provide strong confidence for near to mid-term growth. Looking ahead, we have a catalyst rich pipeline with 15 pivotal readouts in the mid-term. We expect to continue to deliver improved financials and strengthen Novartis ESG foundations, on our journey to become most trusted and valued medicines company in the world”.

Scope of Report

Report Attributes Details
Growth Rate CAGR of 6.1% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in US$ million and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered Drug, Route of Administration, Region
Regions Covered North America; Latin America; Western Europe; Eastern Europe; South Asia & Pacific; East Asia; The Middle East & Africa
Key Countries Profiled The United States, Canada, Brazil, Mexico, Germany, The United Kingdom, France, Spain, Italy, Russia, Poland, Czech Republic, Romania, China, Japan, South Korea, India, Bangladesh, Australia, New Zealand, GCC countries, South Africa, Israel
Key Companies Profiled GlaxoSmithKline; Vectans Pharma; Blistex; Bausch Health; Aurobindo Pharma; Dr. Reddy's Laboratories; Cipla; Jubilant Cadista; Mylan; Novartis International AG
Customization Available Upon Request

Key Segments Profiled in the Herpes Simplex Keratitis Treatment Industry Survey

By Drug:

  • Famciclovir
  • Valacyclovir
  • Acyclovir
  • Other Drugs

By Route of Administration:

  • Topical
  • Injection
  • Oral

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • South Asia & Pacific
  • East Asia
  • The Middle East & Africa

Frequently Asked Questions

What is the Recent Market Valuation?

The market is estimated to secure a valuation of US$ 4,442.2 million in 2023.

What is the Projected Size of the Market by 2033?

The global market size is expected to reach US$ 8,022.9 million by 2033.

What is the Growth Potential of the Market?

The growth potential of the market is 6.1% through 2033.

Which Factor is Helping the Market Advance?

Persistent research and development efforts are helping the market advance.

Which Factor is Derailing the Market Growth?

High cost of herpes simplex keratitis treatment is derailing the market growth.

Table of Content
1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Drug, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug, 2023 to 2033

        5.3.1. Famciclovir

        5.3.2. Valacyclovir

        5.3.3. Acyclovir

        5.3.4. Other Drugs

    5.4. Y-o-Y Growth Trend Analysis By Drug, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033

        6.3.1. Topical

        6.3.2. Injection

        6.3.3. Oral

    6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Western Europe

        7.3.4. Eastern Europe

        7.3.5. South Asia and Pacific

        7.3.6. East Asia

        7.3.7. Middle East and Africa

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        8.2.1. By Country

            8.2.1.1. USA

            8.2.1.2. Canada

        8.2.2. By Drug

        8.2.3. By Route of Administration

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Drug

        8.3.3. By Route of Administration

    8.4. Key Takeaways

9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Drug

        9.2.3. By Route of Administration

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug

        9.3.3. By Route of Administration

    9.4. Key Takeaways

10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. UK

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Western Europe

        10.2.2. By Drug

        10.2.3. By Route of Administration

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug

        10.3.3. By Route of Administration

    10.4. Key Takeaways

11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Poland

            11.2.1.2. Russia

            11.2.1.3. Czech Republic

            11.2.1.4. Romania

            11.2.1.5. Rest of Eastern Europe

        11.2.2. By Drug

        11.2.3. By Route of Administration

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug

        11.3.3. By Route of Administration

    11.4. Key Takeaways

12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Bangladesh

            12.2.1.3. Australia

            12.2.1.4. New Zealand

            12.2.1.5. Rest of South Asia and Pacific

        12.2.2. By Drug

        12.2.3. By Route of Administration

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug

        12.3.3. By Route of Administration

    12.4. Key Takeaways

13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Drug

        13.2.3. By Route of Administration

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug

        13.3.3. By Route of Administration

    13.4. Key Takeaways

14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. South Africa

            14.2.1.3. Israel

            14.2.1.4. Rest of MEA

        14.2.2. By Drug

        14.2.3. By Route of Administration

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug

        14.3.3. By Route of Administration

    14.4. Key Takeaways

15. Key Countries Market Analysis

    15.1. USA

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2022

            15.1.2.1. By Drug

            15.1.2.2. By Route of Administration

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2022

            15.2.2.1. By Drug

            15.2.2.2. By Route of Administration

    15.3. Brazil

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2022

            15.3.2.1. By Drug

            15.3.2.2. By Route of Administration

    15.4. Mexico

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2022

            15.4.2.1. By Drug

            15.4.2.2. By Route of Administration

    15.5. Germany

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2022

            15.5.2.1. By Drug

            15.5.2.2. By Route of Administration

    15.6. UK

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2022

            15.6.2.1. By Drug

            15.6.2.2. By Route of Administration

    15.7. France

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2022

            15.7.2.1. By Drug

            15.7.2.2. By Route of Administration

    15.8. Spain

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2022

            15.8.2.1. By Drug

            15.8.2.2. By Route of Administration

    15.9. Italy

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2022

            15.9.2.1. By Drug

            15.9.2.2. By Route of Administration

    15.10. Poland

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2022

            15.10.2.1. By Drug

            15.10.2.2. By Route of Administration

    15.11. Russia

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2022

            15.11.2.1. By Drug

            15.11.2.2. By Route of Administration

    15.12. Czech Republic

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2022

            15.12.2.1. By Drug

            15.12.2.2. By Route of Administration

    15.13. Romania

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2022

            15.13.2.1. By Drug

            15.13.2.2. By Route of Administration

    15.14. India

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2022

            15.14.2.1. By Drug

            15.14.2.2. By Route of Administration

    15.15. Bangladesh

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2022

            15.15.2.1. By Drug

            15.15.2.2. By Route of Administration

    15.16. Australia

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2022

            15.16.2.1. By Drug

            15.16.2.2. By Route of Administration

    15.17. New Zealand

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2022

            15.17.2.1. By Drug

            15.17.2.2. By Route of Administration

    15.18. China

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2022

            15.18.2.1. By Drug

            15.18.2.2. By Route of Administration

    15.19. Japan

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2022

            15.19.2.1. By Drug

            15.19.2.2. By Route of Administration

    15.20. South Korea

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2022

            15.20.2.1. By Drug

            15.20.2.2. By Route of Administration

    15.21. GCC Countries

        15.21.1. Pricing Analysis

        15.21.2. Market Share Analysis, 2022

            15.21.2.1. By Drug

            15.21.2.2. By Route of Administration

    15.22. South Africa

        15.22.1. Pricing Analysis

        15.22.2. Market Share Analysis, 2022

            15.22.2.1. By Drug

            15.22.2.2. By Route of Administration

    15.23. Israel

        15.23.1. Pricing Analysis

        15.23.2. Market Share Analysis, 2022

            15.23.2.1. By Drug

            15.23.2.2. By Route of Administration

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Drug

        16.3.3. By Route of Administration

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. GlaxoSmithKline

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

        17.1.2. Vectans Pharma

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

        17.1.3. Blistex

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

        17.1.4. Bausch Health

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

        17.1.5. Aurobindo Pharma

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

        17.1.6. Dr. Reddy's Laboratories

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

        17.1.7. Cipla

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

        17.1.8. Jubilant Cadista

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

        17.1.9. Mylan

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

        17.1.10. Novartis International AG

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

        17.1.11. Pfizer Inc.

            17.1.11.1. Overview

            17.1.11.2. Product Portfolio

            17.1.11.3. Profitability by Market Segments

            17.1.11.4. Sales Footprint

            17.1.11.5. Strategy Overview

                17.1.11.5.1. Marketing Strategy

        17.1.12. Sanofi S.A.

            17.1.12.1. Overview

            17.1.12.2. Product Portfolio

            17.1.12.3. Profitability by Market Segments

            17.1.12.4. Sales Footprint

            17.1.12.5. Strategy Overview

                17.1.12.5.1. Marketing Strategy

        17.1.13. Merck & Co., Inc.

            17.1.13.1. Overview

            17.1.13.2. Product Portfolio

            17.1.13.3. Profitability by Market Segments

            17.1.13.4. Sales Footprint

            17.1.13.5. Strategy Overview

                17.1.13.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology
Recommendations

Healthcare

Genital Herpes Treatment Market

July 2021

REP-GB-1390

June 2023

324 pages

Healthcare

Herpes Labialis Treatment Market

December 2021

REP-GB-6461

April 2023

306 pages

Healthcare

Keratitis Treatment Market

January 2023

REP-GB-16525

303 pages

Healthcare

Pain Management Devices Market

February 2022

REP-GB-14306

October 2022

315 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Herpes Simplex Keratitis Treatment Market